Table 2.

Associations of SNPs With Event-Free and Overall Survival in DLBCL in the First and Second Stages and Final Meta-Analysis

SNP and Study	Chromosome	Position	Nearest Gene	Allele		RAF	No. of Patients	Event-Free Survival			Overall Survival
				Risk	Other			HR*	95% CI	P	HR*	95% CI	P
rs7712513	5	121918208	ARGFXP1	C	A
First stage
LYSA-03B						0.35	540	1.40	1.14 to 1.73	.0016	1.48	1.17 to 1.89	.0013
SPORE-I						0.34	312	1.46	1.14 to 1.88	.0028	1.63	1.23 to 2.17	.00077
Meta-analysis (Discovery)								1.43	1.21 to 1.67	1.48 × 10−5	1.54	1.28 to 1.86	3.95 × 10−6
Second stage
SPORE-II						0.31	391	1.33	1.05 to 1.68	.020	1.50	1.13 to 1.98	.0045
GOELAMS-075						0.35	294	1.33	0.97 to 1.84	.079	1.28	0.87 to 1.88	.20
Meta-analysis (all cohorts)								1.39	1.23 to 1.57	2.08 × 10−7	1.49	1.29 to 1.72	3.53 × 10−8
rs7765004	6	114071720	LOC100652953	C	A
First stage
LYSA-03B						0.33	540	1.34	1.08 to 1.68	.0085	1.43	1.11 to 1.84	.0054
SPORE-I						0.30	312	1.52	1.18 to 1.97	.0013	1.43	1.06 to 1.92	.018
Meta-analysis (Discovery)								1.42	1.20 to 1.68	4.35 × 10−5	1.43	1.18 to 1.73	2.65 × 10−4
Second stage
SPORE-II						0.30	391	1.44	1.13 to 1.84	.0030	1.87	1.39 to 2.52	4.00 × 10−5
GOELAMS-075						0.32	294	1.14	0.80 to 1.62	.48	1.04	0.68 to 1.60	.86
Meta-analysis (all cohorts)								1.38	1.22 to 1.57	7.09 × 10−7	1.47	1.27 to 1.71	5.36 × 10−7

Abbreviations: DLBCL, diffuse large B-cell lymphoma; GOELAMS, Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang; HR, hazard ratio; LYSA, Lymphoma Study Association; RAF, risk allele frequency; SNP, single nucleotide polymorphism; SPORE, Specialized Program of Research Excellence.

^*HR and 95% CIs adjusted for age, sex, and age-adjusted International Prognostic Index.